BR112016015057A2 - Compostos e composições farmacêuticas e respectivos usos - Google Patents

Compostos e composições farmacêuticas e respectivos usos

Info

Publication number
BR112016015057A2
BR112016015057A2 BR112016015057A BR112016015057A BR112016015057A2 BR 112016015057 A2 BR112016015057 A2 BR 112016015057A2 BR 112016015057 A BR112016015057 A BR 112016015057A BR 112016015057 A BR112016015057 A BR 112016015057A BR 112016015057 A2 BR112016015057 A2 BR 112016015057A2
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
axl
pyrazolo
directed
Prior art date
Application number
BR112016015057A
Other languages
English (en)
Inventor
L Hudkins Robert
L Zulli Allison
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of BR112016015057A2 publication Critical patent/BR112016015057A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS E COMPOSIÇÕES FARMACÊUTICAS E RESPECTIVOS USOS. A invenção é dirigida a derivados de pirazolo[1,5-a]piridina e seu uso como inibidores AXL e c-MET cinase.
BR112016015057A 2013-12-26 2014-12-18 Compostos e composições farmacêuticas e respectivos usos BR112016015057A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (1)

Publication Number Publication Date
BR112016015057A2 true BR112016015057A2 (pt) 2017-08-08

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015057A BR112016015057A2 (pt) 2013-12-26 2014-12-18 Compostos e composições farmacêuticas e respectivos usos

Country Status (22)

Country Link
US (2) US9914731B2 (pt)
EP (2) EP3309160A1 (pt)
JP (1) JP2017500362A (pt)
KR (1) KR20160110390A (pt)
CN (1) CN106029661B (pt)
AU (1) AU2014370186A1 (pt)
BR (1) BR112016015057A2 (pt)
CA (1) CA2934667A1 (pt)
CL (1) CL2016001604A1 (pt)
DK (1) DK3087070T3 (pt)
EA (2) EA201890061A3 (pt)
ES (1) ES2654931T3 (pt)
HU (1) HUE037579T2 (pt)
IL (1) IL246311A0 (pt)
MX (1) MX2016008445A (pt)
NO (1) NO3014707T3 (pt)
PH (1) PH12016501232A1 (pt)
PL (1) PL3087070T3 (pt)
PT (1) PT3087070T (pt)
SG (1) SG11201605207PA (pt)
SI (1) SI3087070T1 (pt)
WO (1) WO2015100117A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992586A1 (en) * 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
JP7193460B2 (ja) * 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2019101178A1 (zh) * 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN110857293B (zh) * 2018-08-24 2023-01-10 药捷安康(南京)科技股份有限公司 一种新型的喹啉衍生物抑制剂
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
CN116283916B (zh) * 2019-09-06 2024-06-11 中国科学院上海药物研究所 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4371978A1 (en) * 2021-07-13 2024-05-22 Nippon Soda Co., Ltd. Method for producing uracil compound
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
RU2008139599A (ru) * 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
EP2103620A1 (en) * 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
PL2719699T3 (pl) * 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
US9102671B2 (en) * 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
CN103930111A (zh) * 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
ES2614824T3 (es) * 2011-11-14 2017-06-02 Ignyta, Inc. Derivados de uracil como inhibidores de la quinasa axl y c-met
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
AU2014370186A1 (en) 2016-07-14
SI3087070T1 (en) 2018-01-31
SG11201605207PA (en) 2016-07-28
AU2014370186A2 (en) 2016-07-21
CL2016001604A1 (es) 2017-05-26
US9914731B2 (en) 2018-03-13
CN106029661A (zh) 2016-10-12
KR20160110390A (ko) 2016-09-21
IL246311A0 (en) 2016-08-02
PL3087070T3 (pl) 2018-03-30
EP3087070B1 (en) 2017-11-08
NO3014707T3 (pt) 2018-01-06
WO2015100117A1 (en) 2015-07-02
PH12016501232A1 (en) 2016-08-15
JP2017500362A (ja) 2017-01-05
HUE037579T2 (hu) 2018-09-28
EP3309160A1 (en) 2018-04-18
DK3087070T3 (en) 2017-12-04
EP3087070A1 (en) 2016-11-02
EA201890061A3 (ru) 2018-09-28
ES2654931T3 (es) 2018-02-15
US20180148447A1 (en) 2018-05-31
CA2934667A1 (en) 2015-07-02
CN106029661B (zh) 2017-11-03
EA029757B1 (ru) 2018-05-31
EA201890061A2 (ru) 2018-05-31
EA201691164A1 (ru) 2016-12-30
PT3087070T (pt) 2018-01-30
MX2016008445A (es) 2016-10-28
US20160318929A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
BR112016015057A2 (pt) Compostos e composições farmacêuticas e respectivos usos
CR20150395A (es) Derivados de pirrolo[2,3-d] pirimidina
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
CR20150524A (es) Compuestos de heteroarilo y sus usos
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160449A (es) Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
IL240877A0 (en) History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
ES2821394T8 (es) Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos
UY39887A (es) (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7
BR112016006366A2 (pt) uso de picolinamidas macrocíclicas como fungicidas
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
BR112016008994A2 (pt) Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase
UY35747A (es) Derivados sustituidos de fenilalanina
BR112016022342A2 (pt) Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos
HK1219101A1 (zh) 作為 激酶抑制劑的 三唑並 吡啶的衍生物
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
UY35745A (es) Derivados sustituidos de fenilalanina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.